Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

13.12 +0.14 (+1.12%)
Streaming Delayed Price Updated: 10:02 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript ↗
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress ↗
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Analyst Expectations For Regenxbio's Future ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Regenxbio's Earnings ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
7 Analysts Assess Regenxbio: What You Need To Know ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts ↗
 
Via Benzinga
News headline image
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date ↗
Regenxbio reported sustained biomarker reduction and positive neurodevelopmental outcomes in the pivotal CAMPSIITE trial of RGX-121 for MPS II. 
Via Benzinga
News headline image
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year ↗
FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients. 
Via Benzinga
News headline image
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls ↗
REGENXBIO Q2 2025 earnings miss estimates with $21.36M revenue and -$1.38 EPS. Stock drops 2.3% pre-market amid clinical pipeline updates for DMD and diabetic retinopathy therapies. 
Via Chartmill
Topics Earnings
News headline image
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
News headline image
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts ↗
 
Via Benzinga
News headline image
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer ↗
RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch. 
Via Benzinga
News headline image
Dow Dips Over 100 Points; US Jobless Claims Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
Which stocks are gapping on Thursday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
The One-Minute Market Report - Saturday, April 26 ↗
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, ETFs, and stocks that moved the market higher, as well as the market segments that defied the... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial ↗
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile. 
Via Benzinga
News headline image
Signet Jewelers, BGM Group, StoneCo, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.